Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 1, 2014, Pages 140-165

  Merelli, Barbara ^a   Massi, Daniela ^b   Cattaneo, Laura ^a   Mandalà, Mario ^a  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Melanoma; PD 1; PD L1

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; EVEROLIMUS; GEMCITABINE; IPILIMUMAB; LIRILUMAB; MELAN A; MK 3475; NIVOLUMAB; NY ESO 1 ANTIGEN; PACLITAXEL; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; SIPULEUCEL T; UNCLASSIFIED DRUG; AMP 224; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMS 936559; MPDL 3280A; PEMBROLIZUMAB; PEPTIDE VACCINE; TEMOZOLOMIDE; VEMURAFENIB;

ANTIGEN RECOGNITION; BIOLOGICAL FUNCTIONS; CANCER PROGNOSIS; CARCINOID; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE CHECKPOINT; COLORECTAL CANCER; DISEASE COURSE; ESOPHAGUS CANCER; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE ACTIVATION; MELANOMA; METASTATIC MELANOMA; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE MYELOMA; NASOPHARYNX CARCINOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; RECTUM CANCER; REVIEW; SARCOMA; STOMACH CANCER; T LYMPHOCYTE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR IMMUNITY; UTERINE CERVIX CANCER; ADVANCED CANCER; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; COLITIS; DECREASED APPETITE; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; FATIGUE; GASTROINTESTINAL DISEASE; HEPATITIS; HEPATOBILIARY DISEASE; HYPOPHYSITIS; IMMUNE EVASION; IMMUNE RESPONSE; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NON SMALL CELL LUNG CANCER; NONHUMAN; PNEUMONIA; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PRURITUS; RASH; SOLID TUMOR; THYROIDITIS; UROGENITAL TRACT TUMOR; VITILIGO;

MELANOMA; PD-1; PD-L1;

ANIMALS; ANTIGENS, CD274; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 84890888514     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.08.002     Document Type: Review

References (97)

1. Suvà M.L., Riggi N., Bernstein B.E. Epigenetic reprogramming in cancer. Science 2013, 339:1567-1570.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
3. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
4. Hoenicke L., Zender L. Immune surveillance of senescent cells: biological significance in cancer- and non-cancer pathologies. Carcinogenesis 2012, 33:1123-1126.
5. Miska J., Bas E., Devarajan P., Chen Z. Autoimmunity-mediated antitumor immunity: tumor as an immunoprivileged self. Eur J Immunol 2012, 42:2584-2596.
6. Klein G., Klein E. Surveillance against tumors: is it mainly immunologicalα. Immunol Lett 2005, 100:29-33.
7. Legha S.S., Ring S., Bedikian A., et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996, 7:827-835.
8. Legha S.S., Ring S., Eton O., et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998, 16:1752-1759.
9. O'Day S.J., Boasberg P.D., Piro L., et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 2002, 8:2775-2781.
10. Eton O., Legha S.S., Bedikian A.Y., et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002, 20:2045-2052.
11. Atkins M.B., Hsu J., Lee S., et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008, 26:5748-5754.
12. Bajetta E., Del Vecchio M., Nova P., et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 2006, 17:571-577.
13. Keilholz U., Punt C.J., Gore M., et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005, 23:6747-6755.
14. Ridolfi R., Chiarion-Sileni V., Guida M., et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002, 20:1600-1607.
15. Zheng Y.W., Li R.M., Zhang X.W., Ren X.B. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest 2013, 31:197-205.
16. Lafferty K.J., Prowse S.J., Al-Adra A., Warren H.S., Vasalli J., Reich E. An improved assay for interleukin 2 (lymphocyte growth factor) produced by mitogen-activated lymphocytes. Aust J Exp Biol Med Sci 1980, 58:533-544.
17. Viganò S., Perreau M., Pantaleo G., Harari A. Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. Clin Dev Immunol 2012, 2012:4857-4881.
18. Schwartz R.H.A. Cell culture model for T lymphocyte clonal anergy. Science 1990, 248:1349-1356.
19. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
20. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
21. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010, 10:317-327.
22. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
23. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996, 14:233-258.
24. Schwartz R.H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992, 71:1065-1068.
25. Chen L., Ashe S., Brady W.A., et al. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992, 71:1093-1102.
26. Townsend S.E., Allison J.P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993, 259:368-370.
27. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991, 174:561-569.
28. Tai X., Van Laethem F., Sharpe A.H., Singer A. Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation. Proc Natl Acad Sci U S A 2007, 104:13756-13761.
29. Nishimura H., Nose M., Hiai H., Minato N., Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
30. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007, 19:813-824.
31. Long E.O. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999, 17:875-904.
32. Sidorenko S.P., Clark E.A. The dual-function CD150 receptor subfamily: the viral attraction. Nat Immunol 2003, 4:19-24.
33. Raimondi G., Zanoni I., Citterio S., Ricciardi-Castagnoli P., Granucci F. Induction of peripheral T cell tolerance by antigen-presenting B cells. II. Chronic antigen presentation overrules antigen-presenting B cell activation. J Immunol 2006, 176:4021-4028.
34. Freeman G.J., Long A.J., Iwai Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
35. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu Rev Immunol 2005, 23:515-548.
36. Kinter A.L., Godbout E.J., McNally J.P., et al. The common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008, 181:6738-6746.
37. Latchman Y.E., Liang S.C., Wu Y., et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A 2004, 101:10691-10696.
38. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
39. Latchman Y., Wood C.R., Chernova T., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2:261-268.
40. Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 1999, 5:1365-1369.
41. Tseng S.Y., Otsuji M., Gorski K., et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001, 193:839-846.
42. Matsumoto K., Inoue H., Nakano T., et al. B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism. J Immunol 2004, 172:2530-2541.
43. Saresella M., Rainone V., Al-Daghri N.M., Clerici M., Trabattoni D. The PD-1/PD-L1 pathway in human pathology. Curr. Mol. Med. 2012, 12:259-267.
44. Yu M.C., Chen C.H., Liang X., et al. Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology 2004, 40:1312-1321.
45. Dong H., Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J. Mol. Med. 2003, 81:281-287.
46. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
47. Hino R., Kabashima K., Kato Y., et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010, 116:1757-1766.
48. Hamanishi J., Mandai M., Iwasaki M., et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007, 104:3360-3365.
49. Konishi J., Yamazaki K., Azuma M., Kinoshita I., Dosaka-Akita H., Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004, 10:5094-5100.
50. Thompson R.H., Gillett M.D., Cheville J.C., et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004, 101:17174-17179.
51. Nakanishi J., Wada Y., Matsumoto K., Azuma M., Kikuchi K., Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007, 56:1173-1182.
52. Strome S.E., Dong H., Tamura H., et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003, 63:6501-6505.
53. Lyford-Pike S., Peng S., Young G.D., et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013, 73:1733-1741.
54. Ohigashi Y., Sho M., Yamada Y., et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005, 11:2947-2953.
55. Karim R., Jordanova E.S., Piersma S.J., et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009, 15:6341-6347.
56. Ghebeh H., Mohammed S., Al-Omair A., et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006, 8:190-198.
57. Nomi T., Sho M., Akahori T., et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007, 13:2151-2157.
58. Wu C., Zhu Y., Jiang J., Zhao J., Zhang X.G., Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006, 108:19-24.
59. Routh J.C., Ashley R.A., Sebo T.J., et al. B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J Urol 2008, 179:1954-1959.
60. Wintterle S., Schreiner B., Mitsdoerffer M., et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 2003, 63:7462-7467.
61. Hirano F., Kaneko K., Tamura H., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005, 65:1089-1096.
62. Cho Y.A., Yoon H.J., Lee J.I., Hong S.P., Hong S.D. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol 2011, 47:1148-1153.
63. Khalili J.S., Hwu P., Lizée G. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012, 18:5329-5340.
64. Ahmadzadeh M., Johnson L.A., Heemskerk B., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
65. Gadiot J., Hooijkaas A.I., Kaiser A.D., van Tinteren H., van Boven H., Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011, 117:2192-2201.
66. Taube J.M., Anders R.A., Young G.D., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4:127-137.
67. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
68. Hodi F.S., Sznol M., McDermott D.F., et al. Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL). 2012 ASCO annual meeting 2012, J Clin Oncol 30 [suppl; abstr 8507].
69. Hamid O., Robert C., Daud A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
70. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
71. Mkrtichyan M., Najjar Y.G., Raulfs E.C., et al. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J Immunol 2012, 189:2338-2347.
72. Slingluff C.L. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combinationα. Cancer J 2011, 17:343-350.
73. Rosenblatt J., Glotzbecker B., Mills H., et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011, 34:409-418.
74. Pilon-Thomas S., Mackay A., et al. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 2010, 184:3442-3449.
75. Li N., Qin H., Li X., et al. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1. J Clin Immunol 2007, 27:117-130.
76. Palazón A., Teijeira A., Martínez-Forero I., et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res 2011, 71:801-811.
77. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010, 107:4275-4280.
78. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
79. Thompson R.H., Kuntz S.M., Leibovich B.C., et al. Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up. Cancer Res 2006, 66:3381-3385.
80. Mu C.Y., Huang J.-A., Chen Y., Chen C., Zhang X.-G. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011, 28:682-688.
81. Gao Q., Wang X.-Y., Qiu S.-J., et al. Overexpression of PD-L1 Significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009, 15:971-979.
82. Cariani E., Pilli M., Zerbini A., et al. Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS ONE 2012, 7:e32493.
83. Zeng Z., Shi F., Zhou L., et al. Upregulation of circulating PD-L1/PD 1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS ONE 2011, 6:e23621.
84. Hsu M.C., Hsiao J.R., Chang K.C., Wu Y.H., Su I.J., Jin Y.T. Increase of programmed death-1 expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol 2010, 23:1393-1403.
85. Droeser R.A., Hirt C., Viehl C.T., Frey D.M., et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013.
86. Wahlin B.E., Aggarwal M., Montes-Moreno S., et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1 positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010, 16:637-650.
87. Takahashi H., Tomita N., Sakata S., et al. Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era. Eur J Haematol 2013, 90:286-290.
88. Richendollar B.G., Pohlman B., Elson P., Hsi E.D. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum Pathol 2011, 42:552-557.
89. Muenst S., Hoeller S., Dirnhofer S., Tzankov A. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol 2009, 40:1715-1722.
90. Shi F., Shi M., Zeng Z., et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011, 128:887-896.
91. Brahmer J.R., Drake C.G., Wollner I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.
92. Berger R., Rotem-Yehudar R., Slama G., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14:3044-3051.
93. McDermott D.F., Drake C.G., Sznol M., et al. Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC). 2012 ASCO annual meeting 2012, J Clin Oncol 30 [suppl; abstr 4505].
94. Patnaik A., Kang S.P., Tolche A.W., et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. 2012 ASCO annual meeting 2012, J Clin Oncol 30 [suppl; abstr 2512].
95. Kudchadkar R.R., Gallenstein D., Martinez A.J., et al. Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma. 2012 ASCO annual meeting 2012, J Clin Oncol 30 [suppl; abstr 8582].
96. Brahmer J.R., Horn L., Antonia S., et al. Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). 2012 ASCO annual meeting 2012, J Clin Oncol 30 [suppl; abstr 7509].
97. Tykodi S.S., Brahmer J.R., Hwu W.-J., et al. PD-1/PD-L1 pathway as a target for cancer immunotherapy: safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. 2012 ASCO annual meeting 2012, J Clin Oncol 30 [suppl; abstr 2510].